ABSTRACT
INTRODUCTION The National Institute on Aging Late-Onset Alzheimer’s Disease Family Based Study (NIA-LOAD FBS) was established to study the genetic etiology of Alzheimer’s disease (AD).
METHODS Recruitment focused on families with two living affected siblings and a third first degree relative similar in age with or without dementia. Uniform assessments were completed, DNA was obtained as was neuropathology, when possible. APOE genotypes, genome-wide SNP arrays and sequencing was completed in the majority of families.
RESULTS A wide range in the age-at-onset in many large families was related to APOE genotype, but not in all. Variants typically associated with early-onset AD and frontotemporal dementia were also found.
DISCUSSION The NIA-LOAD FBS is the largest collection of familial AD worldwide, and data or samples have been included in 126 publications addressing the genetic etiology of AD. Genetic heterogeneity and variability in the age-at-onset provides opportunities to investigate the complexity of familial AD.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://ncrad.iu.edu/docs/Manual%20of%20Procedures_LOAD.pdf
Funding Statement
The NIA-LOAD FBS supported the collection of samples used in this study through National Institute on Aging (NIA) grants U24AG026395 U24AG021886 R01AG041797 and U24AG056270. Additional families were contributed to the NIA-LOAD FBS through NIH grants: R01AG028786 R01AG027944 RF1AG054074 U01AG052410. None of the authors or their institutions received payment or services from a third party for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Columbia University Irving Medical Center Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The following authors have no relevant conflicts of interest to report: Dolly Reyes, Kelley Faber, Badri Vardarajan, David A. Bennett, Robert A. Sweet, Roger Rosenberg, Margaret A. Pericak-Vance, Jonathan L. Haines, Tatiana Foroud, Richard Mayeux. Dr. Cruchaga has received research support from: Biogen, EISAI, and Alector, and he has consulted or is a member of the advisory board of Vivid genetics, Halia Therapeutics and Takeda and GSK. Dr. Goate has consulted for Eisai, Pfizer, AbbVie, Cognition Therapeutics, Biogen and is on the scientific advisory board at Genentech.
Data Availability
All clinical and genetic data are available to qualified investigators at the National Institute on Aging Genetics of Alzheimer's Disease Storage Site (NIAGADS). Biological Samples related to these data are available to qualified investigators from the National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD)